NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

Get Started

$39.85 -0.18 (-0.45 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$39.85

Today's Range$39.77 - $39.98

52-Week Range$34.52 - $44.53

Volume1.88 million shs

Average Volume2.39 million shs

Market Capitalization$99.25 billion

P/E Ratio13.84

Dividend Yield5.24%

Beta0.82

About GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:GSK

CUSIPN/A

Webwww.gsk.com

Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio3.90

Current Ratio0.61

Quick Ratio0.40

Price-To-Earnings

Trailing P/E Ratio13.84

Forward P/E Ratio13.79

P/E Growth2.1

Sales & Book Value

Annual Sales$38.89 billion

Price / Sales2.54

Cash Flow$3.8207 per share

Price / Cash10.43

Book Value$2.01 per share

Price / Book19.83

Profitability

EPS (Most Recent Fiscal Year)$2.88

Net Income$1.97 billion

Net Margins3.50%

Return on Equity144.84%

Return on Assets10.29%

Miscellaneous

Employees99,827

Outstanding Shares2,479,430,000

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, May 11th will be given a dividend of $0.5298 per share on Thursday, July 12th. This represents a $2.12 annualized dividend and a yield of 5.32%. The ex-dividend date is Thursday, May 10th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings data on Wednesday, April, 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $0.02. The pharmaceutical company had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

13 Wall Street analysts have issued 12 month price objectives for GlaxoSmithKline's stock. Their forecasts range from $35.85 to $40.00. On average, they anticipate GlaxoSmithKline's stock price to reach $38.6167 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:

Ms. Emma Walmsley, Chief Exec. Officer & Director (Age 48)
Mr. Simon P. Dingemans, Chief Financial Officer & Exec. Director (Age 54)
Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)
Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 56)
Mr. Daniel E. Troy, Sr. VP and Gen. Counsel

Has GlaxoSmithKline been receiving favorable news coverage?

Media coverage about GSK stock has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlaxoSmithKline earned a media sentiment score of 0.10 on Accern's scale. They also assigned news coverage about the pharmaceutical company an impact score of 46.73 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (0.86%), Fisher Asset Management LLC (0.54%), Federated Investors Inc. PA (0.17%), Northern Trust Corp (0.13%), Equity Investment Corp (0.13%) and Schafer Cullen Capital Management Inc. (0.08%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Millennium Management LLC, Federated Investors Inc. PA, SeaTown Holdings Pte. Ltd., PVG Asset Management Corp, Envestnet Asset Management Inc., SG Americas Securities LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was acquired by a variety of institutional investors in the last quarter, including Equity Investment Corp, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, BlackRock Inc., LPL Financial LLC, CIBC World Markets Inc., Northern Trust Corp and Summit Trail Advisors LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $39.85.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $99.25 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:		1.7 out of 5 ()
Outperform Votes:		386 (Vote Outperform)
Underperform Votes:		720 (Vote Underperform)
Total Votes:		1,106

MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.

GlaxoSmithKline (NYSE:GSK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

13 Wall Street analysts have issued ratings and price targets for GlaxoSmithKline in the last 12 months. Their average twelve-month price target is $38.6167, suggesting that the stock has a possible downside of 3.09%. The high price target for GSK is $40.00 and the low price target for GSK is $35.85. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.38	2.38	2.29	2.25
Ratings Breakdown:	0 Sell Rating(s) 8 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 8 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$38.6167	$38.6167	$38.2125	$40.95
Price Target Upside:	3.09% downside	3.29% downside	2.53% upside	16.87% upside

GlaxoSmithKline (NYSE:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/9/2018	Deutsche Bank	Reiterated Rating	Neutral		Low
4/4/2018	BNP Paribas	Upgrade	Neutral ➝ Outperform		Medium
3/22/2018	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight		Medium
2/15/2018	Cowen	Reiterated Rating	Hold	$40.00	Low
2/9/2018	Kepler Capital Markets	Upgrade	Reduce ➝ Hold		Low
2/5/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		High
1/16/2018	Barclays	Upgrade	Equal Weight ➝ Overweight		Low
1/15/2018	UBS	Reiterated Rating	Buy		Medium
11/30/2017	Argus	Lower Price Target	Buy	$40.00	Low
11/6/2017	Investec	Downgrade	Buy ➝ Hold		N/A
10/26/2017	Bank of America	Downgrade	Buy ➝ Neutral		N/A
7/27/2017	Citigroup	Reiterated Rating	Neutral		Low
5/26/2017	Berenberg Bank	Upgrade	Hold ➝ Buy		Low
4/5/2017	Exane BNP Paribas	Upgrade	Underperform ➝ Neutral		Low
3/9/2017	Liberum Capital	Initiated Coverage	Buy ➝ Buy		Low
2/19/2017	Jefferies Group	Reiterated Rating	Buy		N/A
12/27/2016	Goldman Sachs Group	Reiterated Rating	Buy		N/A
10/26/2016	Beaufort Securities	Reiterated Rating	Buy		N/A
9/23/2016	Piper Jaffray Companies	Initiated Coverage	Overweight		N/A
8/17/2016	Shore Capital	Reiterated Rating	Hold		N/A

(Data available from 5/26/2016 forward)

GlaxoSmithKline (NYSE:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Earnings Estimates

2018 EPS Consensus Estimate: $3.06

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.69	$0.70	$0.70
Q2 2018	1	$0.82	$0.82	$0.82
Q3 2018	1	$0.86	$0.86	$0.86
Q4 2018	1	$0.68	$0.68	$0.68

GlaxoSmithKline (NYSE GSK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/25/2018
4/25/2018	3/31/2018	$0.70	$0.68	$10.2638 billion	$10.0443 billion	View	N/A
2/7/2018	n/a	$0.69	$0.72	$9.8910 billion	$10.1409 billion	View	N/A
10/25/2017	Q3 2017	$0.84	$0.85	$10.2189 billion	$10.2634 billion	View	N/A
7/26/2017	6/30/2017	$0.68	$0.70	$9.5216 billion	$9.3597 billion	View	N/A
4/26/2017	3/31/2017	$0.62	$0.62	$9.0867 billion	$9.23 billion	View	N/A
2/8/2017	12/31/2016	$0.57	$0.65	$9.2133 billion	$9.4307 billion	View	Listen
10/26/2016	Q316	$0.7730	$0.83	$8.9199 billion	$9.9027 billion	View	Listen
7/27/2016	Q2 2016	$0.55	$0.70	$8.3481 billion	$9.2150 billion	View	N/A
4/27/2016	Q1 2016	$0.60	$0.57	$8.5866 billion	$8.9235 billion	View	N/A
2/3/2016	Q4 2015	$0.52	$0.55	$9.3563 billion	$9.6170 billion	View	N/A
10/28/2015	Q3	$0.60	$0.71	$6.0708 billion	$6.1270 billion	View	N/A
7/29/2015	Q215	$0.4970	$0.53	$9.1446 billion	$9.0198 billion	View	N/A
5/6/2015	Q115	$0.55	$0.48	$8.5525 billion	$8.5123 billion	View	N/A
2/4/2015	Q414	$0.86	$0.82	$6.1427 billion	$6.1860 billion	View	N/A
10/22/2014	Q314	$0.79	$0.90	$9.7556 billion	$9.1195 billion	View	Listen
7/23/2014	Q114	$0.71	$0.65	$10.1307 billion	$9.4721 billion	View	N/A
4/30/2014	Q413	$0.72	$0.70	$10.3571 billion	$9.4402 billion	View	N/A
2/5/2014	Q4	$0.30	$0.30	$6.8377 billion	$6.9060 billion	View	N/A
10/23/2013	Q313		$0.31	$10.31 billion	$10.09 billion	View	N/A
7/24/2013		$0.26	$0.26		$6.6180 billion	View	N/A
4/25/2013	Q1 2013	$0.77	$0.82	$10.1273 billion	$9.8746 billion	View	N/A
2/6/2013	Q4 2012	$0.96	$1.04			View	N/A
10/31/2012	Q3 2012	$0.89	$0.85			View	N/A
7/25/2012	Q2 2012	$0.84	$0.82			View	N/A
4/25/2012		$0.29	$0.2730			View	N/A
2/7/2012		$0.30	$0.2840			View	N/A
10/26/2011	Q3 2011	$0.90	$0.89			View	N/A
7/26/2011	Q2 2011	$0.77	$0.81			View	N/A
4/27/2011	Q1 2011	$1.00	$1.02			View	N/A
2/3/2011	Q4 2010	$0.88	$0.91			View	N/A
7/21/2010	Q2 2010	$0.88	$0.10			View	N/A
4/28/2010	Q1 2010	$0.86	$0.93			View	N/A
2/7/2010	Q4 2009	$1.12	$1.14			View	N/A
11/2/2009	Q3 2009	$0.96	$0.93			View	N/A
7/22/2009	Q2 2009	$0.86	$1.02			View	N/A
2/5/2009	Q4 2008	$0.80	$0.81			View	N/A

(Earnings results data provided by Zacks Investment Research)

GlaxoSmithKline (NYSE:GSK) Dividend Information

GlaxoSmithKline pays an annual dividend of $2.10 per share, with a dividend yield of 5.27%. GSK's next quarterly dividend payment will be made on Thursday, July 12. GlaxoSmithKline pays out 72.92% of its earnings out as a dividend.

Next Dividend:	7/12/2018
Annual Dividend:	$2.10
Dividend Yield:	5.27%
Dividend Growth:	-8.90% (3 Year Average)
Payout Ratio(s):	72.92% (Trailing 12 Months of Earnings) 72.66% (Based on This Year's Estimates) 69.08% (Based on Next Year's Estimates) 54.96% (Based on Cash Flow)
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE:GSK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/26/2018	quarterly	$0.5298	5.27%	5/10/2018	5/11/2018	7/12/2018
2/7/2018	Quarterly	$0.6330	6.48%	2/22/2018	2/23/2018	4/12/2018
10/26/2017	quarterly	$0.5037	5.51%	11/9/2017	11/10/2017	1/11/2018
7/26/2017	Quarterly	$0.4910	4.88%	8/9/2017	8/11/2017	10/12/2017
4/26/2017	quarterly	$0.4830	4.79%	5/10/2017	5/12/2017	7/13/2017
2/8/2017	quarterly	$0.5710	5.76%	2/22/2017	2/24/2017	4/13/2017
10/26/2016		$0.4590		11/2/2016	11/4/2016	1/12/2017
7/27/2016		$0.4940		8/10/2016	8/12/2016	10/13/2016
4/28/2016		$0.5490		5/11/2016	5/13/2016	7/14/2016
10/28/2015		$0.5770		11/10/2015	11/13/2015	1/14/2016
5/7/2015	quarterly	$0.5769	5.22%	5/13/2015	5/15/2015	7/9/2015
2/5/2015	quarterly	$0.6952	6.05%	2/18/2015	2/20/2015	4/9/2015
10/23/2014	quarterly	$0.6130	5.41%	11/5/2014	11/7/2014	1/8/2015
7/24/2014	quarterly	$0.6482	5.18%	8/6/2014	8/8/2014	10/2/2014
5/1/2014	quarterly	$0.64	4.62%	5/14/2014	5/16/2014	7/10/2014
2/5/2014		$0.75		2/19/2014	2/21/2014	4/10/2014
2/6/2014	quarterly	$0.7496	5.73%	2/19/2014	2/21/2014	4/10/2014
10/24/2013	quarterly	$0.6161	4.76%	11/13/2013	11/15/2013	1/9/2014
7/25/2013	quarterly	$0.5532	4.27%	8/7/2013	8/9/2013	10/3/2013
4/25/2013	quarterly	$0.5502	4.25%	5/8/2013	5/10/2013	7/11/2013
2/7/2013	quarterly	$0.0690	0.61%	2/20/2013	2/22/2013	4/11/2013

(Data available from 1/1/2013 forward)

GlaxoSmithKline (NYSE GSK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 11.10%

Insider Trading History for GlaxoSmithKline (NYSE:GSK)

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

GlaxoSmithKline (NYSE GSK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/6/2017	Plc Glaxosmithkline	Major Shareholder	Buy	428,571	$14.00	$5,999,994.00
10/24/2016	Plc Glaxosmithkline	Major Shareholder	Buy	66,500	$14.00	$931,000.00

(Data available from 1/1/2013 forward)

GlaxoSmithKline (NYSE GSK) News Headlines

Source:

Date	Headline
	Venture Capitalists Put $260 Million Into New Chinese Biotech finance.yahoo.com - May 24 at 8:59 AM
	GlaxoSmithKline (GSK) Indian Consumer Unit Receives Frenzy of Interest - Economic Times www.streetinsider.com - May 23 at 4:58 PM
	$0.78 EPS Expected for GlaxoSmithKline (GSK) This Quarter www.americanbankingnews.com - May 22 at 11:10 PM
	BofA/Merrill Lynch Remains Neutral on GlaxoSmithKline (GSK) as FDA and EMA Announce Investigations www.streetinsider.com - May 21 at 5:01 PM
	BRIEF-GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer ... www.reuters.com - May 21 at 5:01 PM
	Regulators flag possible birth defect link to GSK's HIV drug finance.yahoo.com - May 18 at 4:58 PM
	Analysts’ Recommendations for AstraZeneca as of May 15 finance.yahoo.com - May 16 at 5:14 PM
	Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - May 16 at 5:14 PM
	AstraZeneca’s 1Q18 Estimates: CVMD Products finance.yahoo.com - May 16 at 9:30 AM
	Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) Drug Overview 2018: A Fixed-Dose Combination of an ... www.businesswire.com - May 14 at 4:58 PM
	AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study finance.yahoo.com - May 14 at 10:06 AM
	Another tenant inks deal for former GSK campus in RTP www.bizjournals.com - May 12 at 4:59 PM
	Nucala (mepolizumab; GlaxoSmithKline) Drug Overview 2018 - ResearchAndMarkets.com www.businesswire.com - May 11 at 5:22 PM
	What’s behind Teva’s $706 Million Impairment Charges in 1Q18? finance.yahoo.com - May 11 at 5:22 PM
	Form FWP GLAXOSMITHKLINE PLC Filed by: GLAXOSMITHKLINE CAPITAL INC www.streetinsider.com - May 11 at 9:49 AM
	Form FWP GLAXOSMITHKLINE PLC Filed by: GLAXOSMITHKLINE CAPITAL PLC www.streetinsider.com - May 11 at 9:49 AM
	GlaxoSmithKline Target of Unusually Large Options Trading (GSK) www.americanbankingnews.com - May 11 at 6:58 AM
	GlaxoSmithKline (GSK) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - May 10 at 5:45 PM
	June 29th Options Now Available For GlaxoSmithKline (GSK) www.nasdaq.com - May 10 at 4:59 PM
	Merck Focuses on Vaccines and Hospital Specialty Businesses in 2018 finance.yahoo.com - May 10 at 4:59 PM
	Ex-Dividend Reminder: Glaxosmithkline, JM Smucker and Dana www.nasdaq.com - May 8 at 5:05 PM
	Follow These Dividend Leaders For 5% To 12% Yields Plus Upside finance.yahoo.com - May 6 at 5:25 PM
	GlaxoSmithKline (GSK) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - May 5 at 2:27 PM
	Zacks: Analysts Expect GlaxoSmithKline (GSK) to Post $0.78 Earnings Per Share www.americanbankingnews.com - May 5 at 1:24 PM
	Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View finance.yahoo.com - May 4 at 5:11 PM
	Form 6-K GLAXOSMITHKLINE PLC For: May 03 www.streetinsider.com - May 3 at 4:59 PM
	These Pharma Stocks Offer the Most Upside Potential finance.yahoo.com - May 2 at 4:59 PM
	Comparing Analysts’ Views on Sanofi and GlaxoSmithKline finance.yahoo.com - May 2 at 4:59 PM
	GlaxoSmithKline’s Vaccine Business in 1Q18 finance.yahoo.com - April 30 at 9:57 AM
	GlaxoSmithKline Announces Quarterly Dividend of $0.53 (GSK) www.americanbankingnews.com - April 26 at 6:36 PM
	Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid finance.yahoo.com - April 26 at 4:56 PM
	GSK Tries to Fix Pharma on a Budget www.bloomberg.com - April 26 at 8:50 AM
	Currency and pricing squeeze GlaxoSmithKline as new shingles vaccine shines www.cnbc.com - April 25 at 4:58 PM
	Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag finance.yahoo.com - April 25 at 4:58 PM
	Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release finance.yahoo.com - April 25 at 4:58 PM
	Stronger pound weighs on revenues at drugmaker GSK finance.yahoo.com - April 25 at 4:58 PM
	GlaxoSmithKline (GSK) Releases Earnings Results, Misses Estimates By $0.01 EPS www.americanbankingnews.com - April 25 at 2:54 PM
	GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss investorplace.com - April 25 at 12:33 PM
	Stronger pound hinders GlaxoSmithKline www.ft.com - April 25 at 9:11 AM
	Currency and pricing squeeze GSK as new shingles vaccine shines finance.yahoo.com - April 25 at 9:11 AM
	BRIEF-Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The US www.reuters.com - April 24 at 4:55 PM
	Form 6-K GLAXOSMITHKLINE PLC For: Apr 24 www.streetinsider.com - April 24 at 4:55 PM
	Ozempic Could Be Potential Driver for Novo Nordisk in 2018 finance.yahoo.com - April 24 at 4:55 PM
	Form 6-K GLAXOSMITHKLINE PLC For: Apr 20 www.streetinsider.com - April 20 at 5:02 PM
	What's in the Cards for Glaxo (GSK) This Earnings Season? finance.yahoo.com - April 20 at 5:02 PM
	Sanofi to Divest European Generic Unit, Streamline Business finance.yahoo.com - April 19 at 5:22 PM
	GlaxoSmithKline (GSK) Downgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 19 at 12:49 PM
	GlaxoSmithKline (GSK) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - April 19 at 8:47 AM
	GSK grabs Roche cancer expert to lead pharma pipeline deals finance.yahoo.com - April 18 at 4:58 PM
	Novartis’s 1Q18 Estimates: Expectations for Alcon finance.yahoo.com - April 18 at 4:58 PM

GlaxoSmithKline (NYSE:GSK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

GlaxoSmithKline (NYSE:GSK) Income Statement, Balance Sheet and Cash Flow Statement

GlaxoSmithKline (NYSE GSK) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff